Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.85), $0.19 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $84.42 million versus the consensus estimate of $86.02 million.
“2018 was a year of transformation for Sarepta. We continued to execute commercially, announced unprecedented early results in our micro-dystrophin gene therapy program, advanced our RNA strategy with a filing for golodirsen, and, by building out a 25-program/10 therapeutic area genetic medicine portfolio second to no other in biotech, cemented our reputation as a science-focused leader in rare disease,” said Doug Ingram, Sarepta’s president and chief executive officer. “And yet, with all of that progress, we have just begun to execute against our vision. We at Sarepta are dedicated to the proposition that a genetic medicine era is upon us, and we intend to play a central role in translating this promise to a better, longer, richer life for those living with rare disease.”
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.